Internal Medicine, Gastroenterology · Little Rock, AR
NPI
1982828133
Since 2007
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
4301 W Markham St # 783
Little Rock, AR, 72205
Phone (501) 686-8000
Groups this clinician bills Medicare through
Medicare paid, 2024
$169K
2,098 services
Medicare patients, 2024
913
Average age 72
Drug cost, 2024
$274K
3,775 prescriptions
Company payments, 2025
$199
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Pavan Chepyala was code G0500 (moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito), 573 times for 562 patients. In total Pavan Chepyala billed 2,098 services in 39 codes, and Medicare paid $169K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-08-01.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G0500 Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 573 | 562 | $3.22 | $1,846 |
| 45385 Colonoscopy - Lesion Removal | Facility | 339 | 337 | $183.34 | $62K |
| 43239 Upper GI Endoscopy | Facility | 235 | 232 | $47.36 | $11K |
| 99213 Office E&M - Established | Office | 185 | 172 | $58.16 | $11K |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 122 | 122 | $161.59 | $20K |
| 99204 Office E&M - New | Office | 87 | 87 | $96.14 | $8,364 |
| 45380 Lower GI Endoscopy - Other | Facility | 68 | 68 | $87.76 | $5,968 |
| 99203 Office E&M - New | Office | 65 | 65 | $74.54 | $4,845 |
| 99214 Office E&M - Established | Office | 59 | 57 | $87.38 | $5,156 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 57 | 57 | $155.45 | $8,861 |
| 43249 Upper GI Endoscopy | Facility | 50 | 48 | $81.98 | $4,099 |
| 99222 Hospital E&M - Initial | Facility | 35 | 35 | $95.40 | $3,339 |
| 45378 Lower GI Endoscopy - Other | Facility | 32 | 31 | $114.78 | $3,673 |
| 99231 Hospital E&M - Subsequent | Facility | 23 | 19 | $36.13 | $831 |
| 43251 Upper GI Endoscopy | Facility | 20 | 20 | $102.06 | $2,041 |
By year: 2022 $165K for 2,102 services; 2023 $160K for 2,005 services; 2024 $169K for 2,098 services.
Medicare prescription drug claims, 2024
In 2024, the drug Pavan Chepyala prescribed most often to Medicare patients was Peg 3350-Electrolyte (Sodium Chloride/Nahco3/Kcl/Peg), with 718 prescriptions and refills. In total Pavan Chepyala wrote 3,775 Medicare prescriptions that cost $274K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg | 718 | 718 | 702 | $16K |
| Omeprazole Generic | 635 | 1,702 | 190 | $7,248 |
| Pantoprazole Sodium Generic | 594 | 1,582 | 178 | $6,307 |
| Famotidine Generic | 281 | 721 | 93 | $2,278 |
| Colestipol Hcl Generic | 273 | 562 | 85 | $16K |
| Balsalazide Disodium Generic | 117 | 215 | 24 | $21K |
| Gavilyte-N Sodium Chloride/Nahco3/Kcl/Peg | 93 | 93 | 93 | $1,362 |
| Dicyclomine Hcl Generic | 85 | 107 | 28 | $1,318 |
| Esomeprazole Magnesium Generic | 72 | 160 | 15 | $5,605 |
| Lansoprazole Generic | 59 | 146 | 20 | $1,200 |
| Metoclopramide Hcl Generic | 58 | 76 | 20 | $254 |
| Mesalamine Generic | 54 | 119 | 12 | $34K |
| Linzess Linaclotide | 52 | 72 | 13 | $38K |
| Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl | 51 | 51 | 50 | $819 |
| Sucralfate Generic | 49 | 61 | 20 | $699 |
Brand drugs: 339 claims; generic drugs: 3,436 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Pavan Chepyala $199 ($199 in general payments such as food, travel and fees) from 4 companies. The largest payer was Abbvie Inc. with $81.15.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.